Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Sep 15, 2025; 16(9): 109553
Published online Sep 15, 2025. doi: 10.4239/wjd.v16.i9.109553
Published online Sep 15, 2025. doi: 10.4239/wjd.v16.i9.109553
Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosis via miR-29b-3p/SIRT1 signaling pathway in endothelial cells
Yan Guo, Yu-Jie Wang, Zhen-Gang Yang, Liu-Ping Zhang, Department of Cardiology, Traditional Chinese Medical Hospital of Zhuji, Shaoxing 311800, Zhejiang Province, China
Xin-Rou Yu, Ju-Fang Chi, Department of Cardiology, Zhuji Affiliated Hospital of Wenzhou Medical University, Shaoxing 311800, Zhejiang Province, China
Hao-Di Gu, Department of Anesthesiology, Shaoxing People’s Hospital, Shaoxing 312000, Zhejiang Province, China
Hui Lin, Department of Cardiology, Shaoxing People’s Hospital, Shaoxing 312000, Zhejiang Province, China
Hui Lin, Department of Cardiology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo 315211, Zhejiang Province, China
Co-corresponding authors: Liu-Ping Zhang and Hui Lin.
Author contributions: Guo Y, Zhang LP and Lin H designed the research study; Guo Y, Yu XR, Gu HD, and Lin H performed the experiments; Guo Y, Yu XR, Lin H and Chi JF analyzed the data; Guo Y and Zhang LP supervised and funded the project; Guo Y, Wang YJ, Yang ZG, Chi JF and Zhang LP wrote the draft manuscript. All authors contributed to the article and approved the submitted version. This study integrated multidisciplinary expertise requiring distinct supervisory contributions that merit co-corresponding authorship: Dr. Zhang LP served as the project's scientific architect, providing conceptual oversight of the endothelial ferroptosis mechanism and securing funding, Dr. Lin H led the in vitro experiments validation, overseeing diabetic cardiomyopathy model development, directing experimental design and cross-institutional collaboration. Their complementary roles were indispensable: Dr. Zhang LP cardiovascular pathophysiology insights and Dr. Lin H molecular biology expertise enabled comprehensive validation of the FA/miR-29b-3p/SIRT1 axis. Dual designation reflects equal responsibility for intellectual leadership, data integrity, and communication accountability. This structure aligns with ICMJE guidelines recognizing shared senior contributions to complex multidisciplinary projects. Both authors approved the final manuscript and will jointly manage post-publication correspondence.
Supported by Medical Health Science and Technology Project of Zhejiang Provincial, No. 2025KY1721 and No. 2022KY1292; and Science and Technology Projects of Shaoxing City, No. 2022KY104.
Institutional review board statement: The research was approval by the Institutional Animal Care and Use Committee of Shaoxing People’s Hospital (Approval No. 2022KY03901).
Institutional animal care and use committee statement: The research was approval by the Institutional Animal Care and Use Committee of Shaoxing People’s Hospital (Approval No. 2022KY03901).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: All data generated or analyzed during this study are included in this published article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui Lin, MD, PhD, Department of Cardiology, The Affiliated Lihuili Hospital of Ningbo University, No. 57 Xingning Road, Yinzhou District, Ningbo 315211, Zhejiang Province, China. 122525790@qq.com
Received: May 16, 2025
Revised: June 16, 2025
Accepted: August 15, 2025
Published online: September 15, 2025
Processing time: 119 Days and 3.8 Hours
Revised: June 16, 2025
Accepted: August 15, 2025
Published online: September 15, 2025
Processing time: 119 Days and 3.8 Hours
Core Tip
Core Tip: This study was the first to identify the miR-29b-3p/SIRT1 axis as a critical mechanism underlying the attenuation of endothelial ferroptosis and microvascular dysfunction of farrerol (FA) in diabetic cardiomyopathy (DCM). These results highlight the translational potential of targeting miR-29b-3p or administering FA for the treatment of DCM.